SRPT
SRPT
NASDAQ · Biotechnology

Sarepta Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks
$20.48
+0.34 (+1.69%)
As of Sep 22, 1:31 PM ET ·
SRPT News3 articles
Sarepta Surges 13% Despite Delay in Elevidys Safety Trial
Sarepta's stock rallied 13% despite a five-month delay in its Elevidys safety study, as investors weigh the new trial site against weak sales and high short interest.
Markets
Capricor Therapeutics Plunges 67% on FDA Concerns Over Deramiocel Efficacy
Capricor Therapeutics shares plummeted 67% after FDA staff flagged concerns about deramiocel's efficacy data, wiping out $766 million in market value ahead of a key advisory committee vote.
Markets
Arrowhead Sees Volatility After S&P MidCap 400 Inclusion, Goldman Eyes 2026 Pipeline
Arrowhead Pharmaceuticals shares experienced heightened trading activity and a slight decline following its transition to the S&P MidCap 400 index. Goldman Sachs reiterated a Neutral stance, highlighting pivotal 2026 clinical data and competitive pressures.
Markets